Financials Thermo Fisher Scientific Inc. Buenos Aires S.E.

Equities

TMO

ARBCOM4601F7

Advanced Medical Equipment & Technology

End-of-day quote Buenos Aires S.E. Other stock markets 23:00:00 25/06/2024 BST			5-day change	1st Jan Change
34,007 ^ARS	+2.00%		-0.15%	+45.37%

06-27	Barclays Adjusts Price Target on Thermo Fisher Scientific to $600 From $615	MT
06-26	Labguru Announces New Distribution Partnership with Thermo Fisher Scientific of its Electronic Lab Notebook Module to Help Streamline Life Sciences Research	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	130,270	184,605	262,925	216,998	205,083	213,063	-	-
Enterprise Value (EV) ¹	145,623	196,015	293,318	242,962	231,923	236,255	232,200	226,779
P/E ratio	35.4 x	29.2 x	34.3 x	31.2 x	34.4 x	34.8 x	29.9 x	25.6 x
Yield	0.23%	0.19%	0.16%	0.22%	0.26%	0.27%	0.29%	0.32%
Capitalization / Revenue	5.1 x	5.73 x	6.71 x	4.83 x	4.79 x	4.95 x	4.62 x	4.3 x
EV / Revenue	5.7 x	6.08 x	7.48 x	5.41 x	5.41 x	5.49 x	5.04 x	4.58 x
EV / EBITDA	22.3 x	19.2 x	22.6 x	20.3 x	21.3 x	21.9 x	19.6 x	17.4 x
EV / FCF	36 x	28.8 x	41.8 x	35 x	33.5 x	32.3 x	29 x	25.6 x
FCF Yield	2.78%	3.48%	2.39%	2.85%	2.99%	3.09%	3.45%	3.9%
Price to Book	4.38 x	5.39 x	6.45 x	4.89 x	4.39 x	4.3 x	4 x	3.55 x
Nbr of stocks (in thousands)	400,991	396,335	394,048	394,048	386,372	381,716	-	-
Reference price ²	324.9	465.8	667.2	550.7	530.8	558.2	558.2	558.2
Announcement Date	30/01/20	01/02/21	02/02/22	01/02/23	31/01/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	25,542	32,218	39,211	44,915	42,857	43,011	46,078	49,523
EBITDA ¹	6,537	10,214	12,969	11,971	10,878	10,805	11,861	13,049
EBIT ¹	5,973	9,556	12,138	10,985	9,810	9,722	10,731	11,740
Operating Margin	23.39%	29.66%	30.96%	24.46%	22.89%	22.6%	23.29%	23.71%
Earnings before Tax (EBT) ¹	4,070	7,225	8,841	7,835	6,298	7,009	7,967	9,455
Net income ¹	3,696	6,375	7,725	6,950	5,995	6,184	6,962	8,048
Net margin	14.47%	19.79%	19.7%	15.47%	13.99%	14.38%	15.11%	16.25%
EPS ²	9.170	15.96	19.46	17.63	15.45	16.03	18.64	21.77
Free Cash Flow ¹	4,047	6,815	7,020	6,935	6,927	7,307	8,004	8,851
FCF margin	15.84%	21.15%	17.9%	15.44%	16.16%	16.99%	17.37%	17.87%
FCF Conversion (EBITDA)	61.91%	66.72%	54.13%	57.93%	63.68%	67.63%	67.48%	67.83%
FCF Conversion (Net income)	109.5%	106.9%	90.87%	99.78%	115.55%	118.17%	114.97%	109.98%
Dividend per Share ²	0.7600	0.8800	1.040	1.200	1.400	1.492	1.621	1.792
Announcement Date	30/01/20	01/02/21	02/02/22	01/02/23	31/01/24	-	-	-

¹USD in Million²USD

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2
Net sales ¹	10,702	11,818	10,970	10,677	11,450	10,710	10,687	10,574	10,886	10,345	10,521	10,716	11,364	11,110	11,333
EBITDA ¹	3,378	3,700	2,841	2,614	2,816	2,583	2,640	2,829	2,826	2,564	2,552	2,706	2,935	2,797	2,853
EBIT ¹	3,161	3,450	2,605	2,370	2,560	2,330	2,370	2,560	2,550	2,278	2,306	2,461	2,683	2,532	2,602
Operating Margin	29.54%	29.19%	23.75%	22.2%	22.36%	21.76%	22.18%	24.21%	23.42%	22.02%	21.92%	22.96%	23.61%	22.79%	22.96%
Earnings before Tax (EBT) ¹	1,862	2,540	1,917	1,601	1,777	1,363	1,430	1,765	1,740	1,589	1,606	1,759	1,910	1,696	1,782
Net income ¹	1,658	2,215	1,664	1,495	1,576	1,289	1,361	1,715	1,630	1,328	1,419	1,560	1,712	1,494	1,571
Net margin	15.49%	18.74%	15.17%	14%	13.76%	12.04%	12.74%	16.22%	14.97%	12.84%	13.49%	14.56%	15.06%	13.45%	13.86%
EPS ²	4.170	5.610	4.220	3.790	4.010	3.320	3.510	4.420	4.200	3.460	3.727	4.043	4.517	4.260	4.480
Dividend per Share ²	0.2600	0.3000	0.3000	0.3000	0.3000	0.3500	0.3500	0.3500	0.3500	-	0.3861	0.3861	0.3862	0.3982	0.4030
Announcement Date	02/02/22	28/04/22	28/07/22	26/10/22	01/02/23	26/04/23	26/07/23	25/10/23	31/01/24	24/04/24	-	-	-	-	-

¹USD in Million²USD

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	15,353	11,410	30,393	25,964	26,840	23,193	19,138	13,716
Net Cash position ¹	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	2.349 x	1.117 x	2.344 x	2.169 x	2.467 x	2.147 x	1.614 x	1.051 x
Free Cash Flow ¹	4,047	6,815	7,020	6,935	6,927	7,307	8,004	8,851
ROE (net income / shareholders' equity)	17.4%	24.3%	26.5%	21.6%	18.4%	17.1%	17.7%	17.6%
ROA (Net income/ Total Assets)	8.7%	12.3%	9.43%	9.52%	8.54%	7.59%	8.39%	8.7%
Assets ¹	42,502	52,009	81,921	73,003	70,200	81,431	83,025	92,509
Book Value Per Share ²	74.20	86.50	103.0	113.0	121.0	130.0	140.0	157.0
Cash Flow per Share ²	12.30	20.80	24.00	23.20	21.70	21.50	27.90	30.50
Capex ¹	926	1,474	2,523	2,243	1,479	1,493	1,633	1,725
Capex / Sales	3.63%	4.58%	6.43%	4.99%	3.45%	3.47%	3.54%	3.48%
Announcement Date	30/01/20	01/02/21	02/02/22	01/02/23	31/01/24	-	-	-

¹USD in Million²USD

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Thermo Fisher Scientific Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

558.2 USD

Average target price

628.8 USD

Spread / Average Target

+12.65%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
DANAHER CORPORATION	+8.83%	188B
INTUITIVE SURGICAL, INC.	+31.94%	157B
BOSTON SCIENTIFIC CORPORATION	+33.19%	113B
SIEMENS HEALTHINEERS AG	+5.25%	64.85B
EDWARDS LIFESCIENCES CORPORATION	+22.41%	55.17B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+1.34%	49.1B
AGILENT TECHNOLOGIES, INC.	-5.92%	38.83B
GE HEALTHCARE TECHNOLOGIES INC.	+1.94%	35.6B
RESMED, INC.	+11.37%	27.4B

Other Advanced Medical Equipment & Technology